Please assess the completion status of the following clinical trial:

Trial Title: A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:~  * partial small or large bowel resection with primary anastomosis~ * radical cystectomy requiring bowel transection with primary anastomosis~* Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:~  * early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery~ * early ambulation, which is defined as ambulation on Day 1~ * early diet advancement on Day 1~* Planned to receive primary postoperative pain management with opioid analgesia administered by any route.~* American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).~Exclusion Criteria:~* Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.~* Scheduled for endoscopic or laparoscopic surgery.~* Complete bowel obstruction.~* Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).~* More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).~* More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.~* Pregnancy or lactation.~* Presence of peritoneal catheter (for example, for dialysis or chemotherapy).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine 1.25 mg (Type: EXPERIMENTAL): Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
- Naldemedine 2.5 mg (Type: EXPERIMENTAL): Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
- Naldemedine 5 mg (Type: EXPERIMENTAL): Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).